KR20180037693A - A food composition for preventing and improving lung diseases - Google Patents
A food composition for preventing and improving lung diseases Download PDFInfo
- Publication number
- KR20180037693A KR20180037693A KR1020160128172A KR20160128172A KR20180037693A KR 20180037693 A KR20180037693 A KR 20180037693A KR 1020160128172 A KR1020160128172 A KR 1020160128172A KR 20160128172 A KR20160128172 A KR 20160128172A KR 20180037693 A KR20180037693 A KR 20180037693A
- Authority
- KR
- South Korea
- Prior art keywords
- weight
- composition
- lily
- red ginseng
- onion
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 48
- 208000019693 Lung disease Diseases 0.000 title claims abstract description 19
- 235000013305 food Nutrition 0.000 title claims description 13
- 239000000284 extract Substances 0.000 claims abstract description 49
- 235000002789 Panax ginseng Nutrition 0.000 claims abstract description 37
- 241000234435 Lilium Species 0.000 claims abstract description 33
- 235000002732 Allium cepa var. cepa Nutrition 0.000 claims abstract description 24
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 18
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 18
- 235000014443 Pyrus communis Nutrition 0.000 claims abstract description 18
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims abstract description 16
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims abstract description 16
- 229940010454 licorice Drugs 0.000 claims abstract description 16
- 244000291564 Allium cepa Species 0.000 claims abstract 5
- 239000000047 product Substances 0.000 claims description 26
- YEFOAORQXAOVJQ-RZFZLAGVSA-N schisandrol a Chemical compound C1[C@H](C)[C@@](C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-RZFZLAGVSA-N 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 14
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 12
- 240000006024 Lactobacillus plantarum Species 0.000 claims description 10
- 241000894006 Bacteria Species 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 230000009325 pulmonary function Effects 0.000 claims description 7
- 241000186016 Bifidobacterium bifidum Species 0.000 claims description 6
- 241001608472 Bifidobacterium longum Species 0.000 claims description 6
- 229940009291 bifidobacterium longum Drugs 0.000 claims description 6
- 230000002708 enhancing effect Effects 0.000 claims description 6
- 239000004310 lactic acid Substances 0.000 claims description 6
- 235000014655 lactic acid Nutrition 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 239000006228 supernatant Substances 0.000 claims description 6
- 230000006872 improvement Effects 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 230000002829 reductive effect Effects 0.000 claims description 4
- 239000012153 distilled water Substances 0.000 claims description 3
- 238000000855 fermentation Methods 0.000 claims description 3
- 230000004151 fermentation Effects 0.000 claims description 3
- 241000186000 Bifidobacterium Species 0.000 claims description 2
- 240000004160 Capsicum annuum Species 0.000 claims description 2
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 claims description 2
- 235000007862 Capsicum baccatum Nutrition 0.000 claims description 2
- 240000001046 Lactobacillus acidophilus Species 0.000 claims description 2
- 244000199885 Lactobacillus bulgaricus Species 0.000 claims description 2
- 244000199866 Lactobacillus casei Species 0.000 claims description 2
- 235000013958 Lactobacillus casei Nutrition 0.000 claims description 2
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims description 2
- 241001400472 Omiza Species 0.000 claims description 2
- 239000001728 capsicum frutescens Substances 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 229940072205 lactobacillus plantarum Drugs 0.000 claims description 2
- 230000004199 lung function Effects 0.000 claims description 2
- 206010011224 Cough Diseases 0.000 abstract description 20
- 210000004072 lung Anatomy 0.000 abstract description 16
- 208000006673 asthma Diseases 0.000 abstract description 13
- 239000004480 active ingredient Substances 0.000 abstract description 10
- 238000011282 treatment Methods 0.000 abstract description 10
- 235000011511 Diospyros Nutrition 0.000 abstract description 8
- 244000236655 Diospyros kaki Species 0.000 abstract description 7
- 230000001684 chronic effect Effects 0.000 abstract description 7
- 239000000428 dust Substances 0.000 abstract description 6
- 238000005728 strengthening Methods 0.000 abstract description 5
- 208000017574 dry cough Diseases 0.000 abstract description 4
- 206010039083 rhinitis Diseases 0.000 abstract description 4
- 230000002159 abnormal effect Effects 0.000 abstract description 3
- 230000007613 environmental effect Effects 0.000 abstract description 3
- 208000030603 inherited susceptibility to asthma Diseases 0.000 abstract description 3
- 230000002685 pulmonary effect Effects 0.000 abstract description 3
- 240000007049 Juglans regia Species 0.000 abstract description 2
- 235000009496 Juglans regia Nutrition 0.000 abstract description 2
- 244000274050 Platycodon grandiflorum Species 0.000 abstract description 2
- 235000006753 Platycodon grandiflorum Nutrition 0.000 abstract description 2
- 240000006079 Schisandra chinensis Species 0.000 abstract description 2
- 235000008422 Schisandra chinensis Nutrition 0.000 abstract description 2
- 235000020234 walnut Nutrition 0.000 abstract description 2
- 241000282461 Canis lupus Species 0.000 abstract 1
- 240000006890 Erythroxylum coca Species 0.000 abstract 1
- 206010062717 Increased upper airway secretion Diseases 0.000 abstract 1
- 241001619461 Poria <basidiomycete fungus> Species 0.000 abstract 1
- 241001558929 Sclerotium <basidiomycota> Species 0.000 abstract 1
- 241000218220 Ulmaceae Species 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 235000008957 cocaer Nutrition 0.000 abstract 1
- 201000004897 cough variant asthma Diseases 0.000 abstract 1
- 208000026435 phlegm Diseases 0.000 abstract 1
- 230000003449 preventive effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 21
- 241000234282 Allium Species 0.000 description 19
- 241000220324 Pyrus Species 0.000 description 16
- 239000003814 drug Substances 0.000 description 16
- 230000000391 smoking effect Effects 0.000 description 16
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 15
- 206010036790 Productive cough Diseases 0.000 description 15
- 208000024794 sputum Diseases 0.000 description 15
- 210000003802 sputum Anatomy 0.000 description 15
- 240000004371 Panax ginseng Species 0.000 description 14
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 14
- 235000003140 Panax quinquefolius Nutrition 0.000 description 14
- 235000008434 ginseng Nutrition 0.000 description 14
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 230000009471 action Effects 0.000 description 11
- 235000005687 corn oil Nutrition 0.000 description 10
- 239000002285 corn oil Substances 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 201000010099 disease Diseases 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 240000003829 Sorghum propinquum Species 0.000 description 5
- 235000011684 Sorghum saccharatum Nutrition 0.000 description 5
- 235000019658 bitter taste Nutrition 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 235000013372 meat Nutrition 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- 235000019640 taste Nutrition 0.000 description 5
- 206010012735 Diarrhoea Diseases 0.000 description 4
- 206010014561 Emphysema Diseases 0.000 description 4
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 4
- HLXRWTJXGMHOFN-XJSNKYLASA-N Verbenalin Chemical compound O([C@@H]1OC=C([C@H]2C(=O)C[C@H](C)[C@H]21)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HLXRWTJXGMHOFN-XJSNKYLASA-N 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 239000013535 sea water Substances 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 235000018553 tannin Nutrition 0.000 description 4
- 229920001864 tannin Polymers 0.000 description 4
- 239000001648 tannin Substances 0.000 description 4
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 4
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 241000700198 Cavia Species 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 208000000059 Dyspnea Diseases 0.000 description 3
- 206010013975 Dyspnoeas Diseases 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 208000001132 Osteoporosis Diseases 0.000 description 3
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 3
- 235000011613 Pinus brutia Nutrition 0.000 description 3
- 241000018646 Pinus brutia Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 235000019270 ammonium chloride Nutrition 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 206010006451 bronchitis Diseases 0.000 description 3
- 208000013116 chronic cough Diseases 0.000 description 3
- 230000001079 digestive effect Effects 0.000 description 3
- 230000001882 diuretic effect Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- -1 methylzantine system Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 230000000241 respiratory effect Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 230000007958 sleep Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 230000035900 sweating Effects 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241001474374 Blennius Species 0.000 description 2
- 206010006448 Bronchiolitis Diseases 0.000 description 2
- 206010006458 Bronchitis chronic Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- YTZSBJLNMIQROD-SFBCHFHNSA-N Morroniside Chemical compound O([C@@H]1OC=C([C@H]2C[C@H](O)O[C@@H](C)[C@H]21)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YTZSBJLNMIQROD-SFBCHFHNSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 241000237502 Ostreidae Species 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 208000019802 Sexually transmitted disease Diseases 0.000 description 2
- HLXRWTJXGMHOFN-UHFFFAOYSA-N Verbenalin Natural products C12C(C)CC(=O)C2C(C(=O)OC)=COC1OC1OC(CO)C(O)C(O)C1O HLXRWTJXGMHOFN-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006533 astragalus Nutrition 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 229940002008 bifidobacterium bifidum Drugs 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 208000007451 chronic bronchitis Diseases 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000010411 cooking Methods 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 229940039696 lactobacillus Drugs 0.000 description 2
- 150000002617 leukotrienes Chemical class 0.000 description 2
- 235000011477 liquorice Nutrition 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229940126601 medicinal product Drugs 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000003607 modifier Substances 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 235000020636 oyster Nutrition 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229960004559 theobromine Drugs 0.000 description 2
- 229960000278 theophylline Drugs 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- YTZSBJLNMIQROD-UHFFFAOYSA-N (4aS)-1c-beta-D-glucopyranosyloxy-6xi-hydroxy-8t-methyl-(4ar,8ac)-5,6,8,8a-tetrahydro-1H,4aH-pyrano[3,4-c]pyran-4-carboxylic acid methyl ester Natural products C12C(C)OC(O)CC2C(C(=O)OC)=COC1OC1OC(CO)C(O)C(O)C1O YTZSBJLNMIQROD-UHFFFAOYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 206010001382 Adrenal suppression Diseases 0.000 description 1
- 208000000884 Airway Obstruction Diseases 0.000 description 1
- 235000013479 Amaranthus retroflexus Nutrition 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- 240000005674 Ceanothus americanus Species 0.000 description 1
- 235000014224 Ceanothus americanus Nutrition 0.000 description 1
- 235000001904 Ceanothus herbaceus Nutrition 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 206010009866 Cold sweat Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 244000055850 Diospyros virginiana Species 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010014568 Empyema Diseases 0.000 description 1
- 208000008967 Enuresis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241001522296 Erithacus rubecula Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 206010018092 Generalised oedema Diseases 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 206010019133 Hangover Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 241000721662 Juniperus Species 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- AMBQHHVBBHTQBF-UHFFFAOYSA-N Loganin Natural products C12C(C)C(O)CC2C(C(=O)OC)=COC1OC1OC(CO)C(O)C(O)C1O AMBQHHVBBHTQBF-UHFFFAOYSA-N 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 206010028735 Nasal congestion Diseases 0.000 description 1
- 206010052437 Nasal discomfort Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 206010073310 Occupational exposures Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 241000276427 Poecilia reticulata Species 0.000 description 1
- 206010036018 Pollakiuria Diseases 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 244000299790 Rheum rhabarbarum Species 0.000 description 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 240000008866 Ziziphus nummularia Species 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000009798 acute exacerbation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000003915 air pollution Methods 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- JBDGDEWWOUBZPM-XYPYZODXSA-N ambroxol Chemical compound NC1=C(Br)C=C(Br)C=C1CN[C@@H]1CC[C@@H](O)CC1 JBDGDEWWOUBZPM-XYPYZODXSA-N 0.000 description 1
- 229960005174 ambroxol Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- 230000007234 antiinflammatory process Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 229940124748 beta 2 agonist Drugs 0.000 description 1
- 229940125388 beta agonist Drugs 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 230000010083 bronchial hyperresponsiveness Effects 0.000 description 1
- 210000003123 bronchiole Anatomy 0.000 description 1
- 230000007885 bronchoconstriction Effects 0.000 description 1
- 230000003182 bronchodilatating effect Effects 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000005482 chemotactic factor Substances 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 229940124446 critical care medicine Drugs 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000013367 dietary fats Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002888 effect on disease Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000021107 fermented food Nutrition 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000021022 fresh fruits Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000005095 gastrointestinal system Anatomy 0.000 description 1
- 239000010520 ghee Substances 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000009548 growth disturbance Effects 0.000 description 1
- 235000001497 healthy food Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 210000001624 hip Anatomy 0.000 description 1
- 235000011157 hong shi Nutrition 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000005470 impregnation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 235000015094 jam Nutrition 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- AMBQHHVBBHTQBF-UOUCRYGSSA-N loganin Chemical compound O([C@@H]1OC=C([C@H]2C[C@H](O)[C@H](C)[C@H]21)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O AMBQHHVBBHTQBF-UOUCRYGSSA-N 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 239000012907 medicinal substance Substances 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000036640 muscle relaxation Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 231100000675 occupational exposure Toxicity 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 210000005037 parasympathetic nerve Anatomy 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000010204 pine bark Nutrition 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 208000008423 pleurisy Diseases 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 235000013324 preserved food Nutrition 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 229960004017 salmeterol Drugs 0.000 description 1
- 235000019643 salty taste Nutrition 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 230000005586 smoking cessation Effects 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000019614 sour taste Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 208000018556 stomach disease Diseases 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 208000009852 uremia Diseases 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 208000022934 urinary frequency Diseases 0.000 description 1
- 230000036318 urination frequency Effects 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 235000014101 wine Nutrition 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/065—Microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/314—Foods, ingredients or supplements having a functional effect on health having an effect on lung or respiratory system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/113—Acidophilus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/123—Bulgaricus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/125—Casei
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/169—Plantarum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/517—Bifidum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/533—Longum
-
- A23Y2220/03—
-
- A23Y2220/15—
-
- A23Y2220/17—
-
- A23Y2220/67—
-
- A23Y2300/25—
-
- A23Y2300/55—
Abstract
Description
본 발명은 폐질환 예방 및 개선을 위한 조성물에 관한 것으로, 보다 구체적으로는 배, 홍시, 호도육, 홍삼, 길경, 백합, 숙지황, 백복령, 유근피, 오미자, 양파, 산수유 및 감초로 이루어진 혼합 추출물의 발효물을 유효성분으로 포함하는 폐기능 강화 또는 폐질환 예방 및 개선을 위한 식품 조성물에 관한 것이다. The present invention relates to a composition for prevention and improvement of pulmonary disease, and more particularly, to a composition for prevention and improvement of pulmonary disease, and more particularly to a composition for prevention and improvement of pulmonary disease, A fermented product as an active ingredient, and a food composition for prevention and improvement of pulmonary disease.
천식과 함께 대표적인 폐질환의 하나인 만성폐쇄성 폐질환(Chronic Obstructive Pulmonary Disease, COPD)은 비가역적인 기도의 폐색을 동반한다는 점에서 천식과 다르며 현재 세계 사망률 4위를 차지하고 있고, 10대 질환 중 유일하게 그 발병률이 증가하는 중요한 질환이다. COPD는 기도 및 폐실질 염증에 의한 세기관지 및 폐실질의 병리학적 변화에 의해 발생하는 병으로, 폐쇄성 세기관지염 및 폐기종(폐실질 파괴)을 특징으로 한다. 만성폐쇄성폐질환(Chronic Obstructive Pulmonary Disease)의 종류에는 만성폐쇄성기관지염(Chronic obstructive bronchitis), 만성세기관지염(Chronic bronchiolitis) 및 폐기종(Emphysema)이 있다. COPD 원인 중 흡연은 가장 중요한 원인으로 생각되고 있다. 흡연은 폐 조직내 강한 독성물질로 작용하여, 산화물질, 전염증인자 및 화학주성인자의 생성을 촉진하게 되고, 이는 호중구와 같은 염증세포들의 과도한 이주를 촉진하게 된다. Chronic Obstructive Pulmonary Disease (COPD), one of the most common pulmonary diseases with asthma, differs from asthma in that it is associated with irreversible airway obstruction. It currently occupies the fourth highest global mortality rate, It is an important disease that the incidence increases. COPD is a disease caused by a pathologic change of bronchioles and lung parenchyma caused by airway and pulmonary parenchymal inflammation, characterized by obstructive bronchiolitis and emphysema (pulmonary parenchymal destruction). Types of Chronic Obstructive Pulmonary Disease include Chronic obstructive bronchitis, Chronic bronchiolitis, and Emphysema. Smoking is one of the most important causes of COPD. Smoking acts as a strong toxic substance in the lung tissue, promoting the production of oxidants, proinflammatory and chemotactic factors, which promotes excessive migration of inflammatory cells such as neutrophils.
지금까지 천식을 비롯한 COPD의 경우 염증성 질환의 치료를 위해 항염증 작용이나 기관지확장 효과를 갖는 치료제를 이용하여 왔다. 그런 기존의 상당수 치료제들은 많은 부작용으로 사용시 주의를 요하고 있다. 대표적인 치료제는 글루코콜티코이드 (glucocorticoid), 루코트리엔 모디파이어(leukotriene modifiers), 데오필린(theophylline) 등이 있다. 글루코콜티코이드(glucocorticoid)는 효과 면에서는 강력하나 선택적으로 작용하는 것이 아니라 모든 면역반응과 항염증반응을 억제하기 때문에 경우에 따라서 필요한 면역반응까지 억제하는 문제점이 있으며, 약물부작용이 문제가 되어 흡입 치료를 시행하고 있다. 루코트리엔 모디파이어 (leukotriene modifiers)는 부작용은 적지만 효과 면에서 한계가 있어 단독으로 사용 시에는 천식을 조절할 수 없어, 대부분 보조적으로 사용하고 있는 문제점이 있다. 데오필린(theophylline)은 효과 면에서도 뛰어나지 못하며 부작용의 우려가 있는 문제점이 있다. 코르티코스테로이드 (corticosteroid) 제제는 뛰어난 치료 효과를 나타내지만 장기적으로 사용할 경우 용량과 사용시간에 비례하여 부신 억제, 골밀도 감소, 성장 장애, 눈과 피부의 합병증, 콜라겐의 합성 증가 등을 유발하는 것으로 알려져 있다. 살메테롤 (salmeterol)과 포르메테롤 (formeterol)과 같은 지속성 베타-2 길항제 (beta-2 agonist)는 발작에 대해 예방 효과를 나타내지만 경우에 따라서는 환자를 사망케 할 수도 있다고 경고된 바 있다. 이와 같은 다양한 부작용들로 인해 종래의 염증성 질환의 치료제들은 그 사용에 있어 신중한 고려가 필요하며, 효과가 뛰어나고 부작용이 적은 치료제의 개발이 절실히 요구되고 있다. 이를 위해서는 COPD의 발생기전에 대한 정확한 이해가 필요하다. Up to now, COPD, including asthma, has been used for the treatment of inflammatory diseases with therapeutic agents having antiinflammatory or bronchodilating effects. Many of these existing treatments require many caution when used with many side effects. Representative therapeutic agents include glucocorticoid, leukotriene modifiers, theophylline, and the like. Glucocorticoid is powerful but not selective, but it suppresses all immune and anti-inflammatory reactions. Therefore, there is a problem of suppressing the necessary immune response in some cases. As a result of drug side effects, Treatment. Although leukotriene modifiers have few side effects, they have limited efficacy and can not control asthma when used alone. Theophylline is not excellent in efficacy and has a problem of side effects. Although corticosteroids have excellent therapeutic effects, they are known to cause adrenal suppression, bone density reduction, growth disturbance, eye and skin complications, and increased collagen synthesis in proportion to the dose and duration of use, . A persistent beta-2 agonist, such as salmeterol and formeterol, has been shown to prevent seizures, but it has been warned that it may lead to death in some cases . Due to these various side effects, conventional therapeutic agents for inflammatory diseases require careful consideration in their use, and there is a desperate need for the development of therapeutic agents with excellent effects and few side effects. This requires an accurate understanding of the origin of COPD.
한편, COPD와 관련하여 현재까지 정확한 발생기전은 거의 알려져 있지 않으며, 여러 가지 치료방법이 사용되고 있으나 발병 및 경과 진행을 근본적으로 치료할 수 있는 약제는 없는 실정이다. 따라서 COPD의 병인 기전 연구 및 이에 근거한 근본적 약제 개발이 절실한 실정이다.In the meantime, the precise mechanism of COPD is unknown until now, and various treatment methods have been used. However, there is no medicament that can fundamentally treat the onset and progress of COPD. Therefore, it is necessary to study the pathogenesis mechanism of COPD and to develop basic medicine based on it.
폐기능을 떨어뜨리는 여러 가지 요인이 있겠지만, 그 중에서 가장 심각한 것이 흡연이다. WHO의 보고서에 따르면, 현재 남자는 세계인구의 47%, 여자는 12%가 담배를 피우고 있으며 매년 350만명이 흡연관련 질병으로 사망하고 있다고 보고하고 있고, 2020년에는 흡연자의 비율이 전체의 12%를 넘어서 매년 1천만명이 희생될 것이라고 전망하고 있다. There may be several factors that can reduce lung function, but the most serious of these is smoking. According to the WHO report, 47% of the world's population and 12% of women are smoking now, and 3.5 million people die from smoking-related diseases every year. In 2020, the proportion of smokers is 12% Which is expected to cost 10 million people every year.
담배연기에는 여러 가지 유해물질이 다량 함유되어 있는데, 주로 입자상으로 포함되어 있는 니코틴, 기상에 포함되어 있는 이산화탄소가 생리적으로 영향을 준다. 습관성 흡연의 영향으로는 폐, 인두, 구강, 후두, 식도, 위, 방광, 신우, 요관, 췌장 등의 암, 허혈성심질환, 뇌혈관질환, 만성폐색성 폐질환, 저 출생 체중아 및 유, 조산 등이 거론되고 있다. Tobacco smoke contains a large amount of various harmful substances, mainly nicotine, which is contained in particulate matter, and carbon dioxide contained in the gas phase physiologically influence it. Effects of addictive smoking include cancers such as lung, pharynx, oral cavity, larynx, esophagus, stomach, bladder, pelvis, ureter, pancreas, ischemic heart disease, cerebrovascular disease, chronic obstructive pulmonary disease, This is being discussed.
또한, 흡연자 주의의 간접 흡연자에 대한 폐해도 커서 여러 사람이 모이는 공공장소에서 흡연을 하다 적발되는 경우에는 과태료를 부과하도록 각 지자체에서 규정하고 있고, 최근에는 식당을 포함하는 몇 몇 장소에서 흡연하는 경우에도 과태료가 부과되고, 길거리에서 흡연을 하는 경우에 따른 길거리 흡연 금지법안이 제출되는 등 흡연으로 인한 폐해를 예방하기 위한 여러 가지 노력이 이루어지고 있다. In addition, smokers are exposed to secondhand smokers, so they are required to pay a penalty if they are caught smoking in public places where many people gather. In recent years, smokers have been smoking in some places including restaurants There are also various efforts to prevent the harm caused by smoking, such as the imposition of a fine on street fines and a bill to prohibit street smoking due to smoking in the streets.
흡연으로 인한 질병 폐해가 크지만 반면에 금연하는 경우에는 건강회복효과 또한 크다고 알려져 있다. 예를 들면, 금연 1년 정도가 경과하면 심장병으로 발전하는 관상동맥질환 발생 위험율이 50% 줄어들고, 15년이 지나면 폐암과 뇌졸중도 들어든다고 한다. It is known that the effect of health recovery is also great when the illness caused by smoking is great but smoking cessation is large. For example, one year after quitting smoking, the risk of developing coronary heart disease is reduced by 50%, and 15 years later, lung cancer and stroke are also included.
또한 흡연 외에도 최근에는 중국으로부터 중금속이 다량 함유된 황사나 미세먼지 등이 우리나라에 까지 영향을 미치고 있으며 한 때는 봄철에 집중적으로 발생하였으나 근래에는 계절을 불문하고 발생하고 있어 어린이나 노약자 등의 기관지 및 폐에 악영향을 미칠 것이 우려되고 있다. In addition to smoking, recently, yellow dust and fine dusts containing heavy metals from China have been affecting Korea, and at one time they have been concentrated in spring. Recently, however, they have occurred regardless of the season, There is a fear that it will have an adverse effect on the environment.
황사나 미세먼지로부터 기관지나 폐를 보호하기 위해서는 일반적으로는 마스크를 사용하거나 귀가 후 세척하는 정도를 실천하고 있으나 그에 더해 추가적인 노력이 필요한 실정이다. In order to protect the lungs or lungs from dust or fine dust, it is generally necessary to use a mask or to clean after the ear, but additional efforts are needed.
이에 본 발명자들은 폐기능을 강화하여 폐질환을 예방할 수 있으며, 미세먼지 및 각종 환경오염으로부터 폐를 보호할 수 있는 천연유래 물질을 개발하기 위하여 계속 연구를 진행하던 중 배, 홍시, 호도육, 홍삼, 길경, 백합, 숙지황, 백복령, 유근피, 오미자, 양파, 산수유 및 감초로 이루어진 혼합 추출물의 발효물이 폐음부족으로 마른기침, 가래, 몸이 수척하고 기운이 없을 때에 복용하면 기력이 상승하고 폐를 보하여 만성적 폐질환을 예방 치료 할 수 있다는 것을 확인하고 본 발명을 완성하였다. Accordingly, the present inventors have conducted intensive studies to develop a natural-derived material capable of preventing lung disease by enhancing pulmonary function and protecting lungs from fine dusts and various environmental pollutants. When the fermented product of mixed extract consisting of Gyungyang, Lily, Seokjanghwang, Baekbokryeong, Yukunpie, Omija, onion, corn oil and licorice is used when the dry cough, sputum and body are not smooth and weak, The present invention has been accomplished based on this finding.
따라서, 본 발명에서 해결하고자 하는 기술적 과제는 폐기능 강화 및 폐질환 예방 또는 개선용 식품 조성물을 제공하는 것이다.Accordingly, it is a technical object of the present invention to provide a food composition for enhancing pulmonary function and preventing or improving pulmonary disease.
상기한 기술적 과제를 해결하기 위하여, 본 발명에서는 배, 홍시, 호도육, 홍삼, 길경, 백합, 숙지황, 백복령, 유근피, 오미자, 양파, 산수유 및 감초의 혼합 추출물을 유산균으로 발효시킨 추출 발효물을 유효성분으로 포함하는 폐기능 강화 또는 폐질환 예방 및 개선을 위한 식품 조성물을 제공한다.In order to solve the above technical problems, the present invention provides an extract fermented product obtained by fermenting a mixed extract of Bae, Hongxi, Hodo, Red ginseng, Gyungyang, Lily, Seokjanghwang, Baekbokryeong, Yukuni, Omija, Onion, A food composition for enhancing pulmonary function or preventing or improving pulmonary disease as an active ingredient is provided.
바람직한 하나의 구현예에 따르면, 본 발명에서는 배 25 내지 35 중량%, 홍시 15 내지 25%, 호도육 5 내지 15 중량%, 홍삼 3 내지 5 중량%, 길경 3 내지 5 중량%, 백합 3 내지 5 중량%, 숙지황 3 내지 5 중량%, 백복령 3 내지 5 중량%, 유근피 3 내지 5 중량%, 오미자 3 내지 5 중량%, 양파 3 내지 5 중량%, 산수유 3 내지 5 중량% 및 감초 3 내지 5 중량%로 이루어진 혼합 추출물의 발효물을 유효성분으로 포함하는 폐기능 강화 및 폐질환 예방 또는 개선을 위한 식품 조성물을 제공한다.According to one preferred embodiment of the present invention, the present invention provides a method for producing a pearl of the present invention which comprises blending 25 to 35% by weight of pear, 15 to 25% of pear, 5 to 15% of pear, 5 to 15% 3 to 5% by weight of oyster, 3 to 5% by weight of onion, 3 to 5% by weight of corn oil, 3 to 5% by weight of licorice, 3 to 5% % Of a fermented product of a mixed extract as an active ingredient, and a food composition for preventing or improving pulmonary disease.
본 발명에서 용어, "만성 폐쇄성 폐질환"은 유해한 입자나 가스의 흡입에 의해 폐에 비정상적인 염증 반응이 일어나면서 이로 인해 점차 기류 제한이 진행되어 폐 기능이 저하되고 호흡곤란을 유발하게 되는 호흡기 질환을 말한다. 만성폐쇄성 폐질환의 주된 증상은 만성적인 기침 또는 만성적인 가래(객담)을 비롯하여 호흡곤란 등이 있으며, 베타항진제, 항콜린제, 메틸잔틴계 등의 기관지 확장제 또는 부신피질 호르몬 흡입제 등이 대표적인 치료제로 사용된다. 본 발명에서 상기 만성폐쇄성 폐질환은 바람직하게는 만성 기관지염(chronic bronchitis) 또는 폐기종(emphysema)일 수 있으나, 이에 제한되지 않는다.In the present invention, the term "chronic obstructive pulmonary disease" refers to a respiratory disease caused by an abnormal inflammatory reaction caused by inhalation of harmful particles or gas, It says. The main symptoms of chronic obstructive pulmonary disease are chronic cough or chronic sputum (sputum) as well as dyspnea, and bronchodilator such as beta agonist, anticholinergic agent, methylzantine system, or corticosteroid inhalant do. In the present invention, the chronic obstructive pulmonary disease may be, but is not limited to, chronic bronchitis or emphysema.
본 발명에서 용어, "만성 기관지염(chronic bronchitis)"이란, 2년 연속, 1년에 3개월 이상 가래가 있고 기침이 지속되는 질환을 의미한다. 흡연, 대기오염, 직업적 노출 등의 자극에 의한 기관지 손상이 원인으로 추정되고 있으며, 주요 증상으로는 만성 기침, 가래, 운동시 호흡곤란 등이 있다. 또한, 만성폐쇄성 폐질환의 특징인 급성 악화가 있을 수 있으며, 이때에는 수시간에서 수일 사이 호흡곤란이 빠르게 악화되고 가래의 양이 늘어나거나 가래의 성상이 점액성에서 화농성으로 변하면서 진한 노란색이나 푸르스름한 색을 띄게 되고 점도가 높아져 뱉어내기 힘들어진다.The term "chronic bronchitis " in the present invention means a disease in which the sputum is persistent for two consecutive years, three months or more per year, and cough persists. It is presumed that bronchial damage caused by stimulation of smoking, air pollution, occupational exposure, etc., is the main symptom, such as chronic cough, sputum and dyspnea during exercise. In addition, there may be acute exacerbation of chronic obstructive pulmonary disease. In this time, the breathing difficulty rapidly deteriorates from several hours to several days, the quantity of sputum increases, or the characteristic of sputum changes from mucous to purulent, and dark yellow or bluish It becomes colored and becomes viscous, making it difficult to spit.
본 발명에서 용어, "폐기종(emphysema)"이란, 종말 세기관지(terminal bronchiole) 원위부 공기공간(airspace)의 파괴로 인하여 비정상적이며 영구적인 말초 기도 및 폐포의 확장상태를 의미한다. 유해 입자와 가스의 흡입에 의하여 발생하며, 임상적으로 가장 의미있는 위험인자는 흡연으로 알려져 있다. 주요 증상으로는 만성적인 기침과 가래, 호흡곤란 등이 있다.The term "emphysema " in the present invention means an abnormal and permanent peripheral airway and alveolar expansion due to the destruction of the distal bronchioleast airspace. It is caused by inhalation of harmful particles and gas. The most clinically significant risk factor is known as smoking. The main symptoms are chronic cough, sputum and dyspnea.
본 발명에서 사용된 용어, "예방"은 본 발명에 따른 조성물의 투여로 만성폐쇄성폐질환을 비롯한 다발성 경화증, 급성 및 만성 폐질환의 발병을 억제 또는 지연시키는 모든 행위를 말한다.As used herein, the term "prophylactic " refers to any act that inhibits or delays the onset of multiple sclerosis, acute and chronic pulmonary disease, including chronic obstructive pulmonary disease by administration of the composition according to the present invention.
본 발명의 조성물에서는 배 25 내지 35 중량%, 홍시 15 내지 25%, 호도육 5 내지 15 중량%, 홍삼 3 내지 5 중량%, 길경 3 내지 5 중량%, 백합 3 내지 5 중량%, 숙지황 3 내지 5 중량%, 백복령 3 내지 5 중량%, 유근피 3 내지 5 중량%, 오미자 3 내지 5 중량%, 양파 3 내지 5 중량%, 산수유 3 내지 5 중량% 및 감초 3 내지 5 중량%로 사용되는 것이 특징이다.In the composition of the present invention, the composition of the present invention contains 25 to 35% by weight of pear, 15 to 25% of horseshoe, 5 to 15% by weight of horsemeat, 3 to 5% by weight of red ginseng, 3 to 5% by weight of ginseng, 3 to 5% 3 to 5% by weight of oyster, 3 to 5% by weight of onion, 3 to 5% by weight of corn oil and 3 to 5% by weight of licorice to be.
상기 배는 생과일로 먹거나 주스, 통조림, 잼, 배숙 등을 만들어 먹을 수 있다. 배에는 연육효소가 있어 단백질의 연육을 도와 부드럽게 먹을 수 있으며, 배는 칼로리가 낮아 비만인 사람에게 좋은 과일이다. 배에 많이 들어 있는 펙틴은 혈중 콜레스테롤 수치를 낮춰주고 수분 부족으로 변비가 생겼을 때 변을 부드럽게 해 변비를 예방하는 효능이 있다.The boat can be eaten as a fresh fruit, juice, canned food, jam, and boiled sake. The abalone has an abundance of enzymes that can help soften the protein and soften it. The belly is low in calories and is good for obese people. Pectin, which is abundant in the abdomen, lowers the cholesterol level in the blood, and when there is a lack of water due to lack of water, it softens the stool to prevent constipation.
상기 홍시는 연시 또는 연감이라고도 한다. 홍시는 감의 색깔이 붉다는 측면에서 붙여진 명칭이고, 연시는 질감이 말랑말랑하고 부드럽다는 측면에서 붙여진 명칭이다. 감은 단감과 떫은감으로 구분되는데, 한국의 재래종 감은 모두 떫은감이다. 떫은감은 다시 완전 떫은감과 불완전 떫은감, 불완전 단감으로 세분된다. 감이 떫은맛을 내는 것은 감 속에 디오스프린이라는 타닌 성분을 함유되어 있기 때문이다. 이 성분은 수용성(水溶性)이기 때문에 입 안에서 침과 섞여 녹아서 떫은맛을 내는 것이다. 이 떫은맛을 제거하는 것을 탈삽(脫澁)이라고 한다. 탈삽에는 자연적으로 떫은맛이 사라지고 말랑말랑해져서 단맛이 들도록 저장해 두는 방법과 인위적으로 떫은맛을 제거하는 방법이 있다. 인위적인 방법에는 농가에서 전통적으로 전해온 온탕탈삽법을 비롯하여 알코올탈삽법·가스탈삽법·동결탈삽법 등이 이용된다. 여기서 탈삽은 수용성 타닌 성분을 불용성(不溶性)으로 변화시키는 것일 뿐이며, 타닌 성분까지 제거하는 것은 아니다. 《동의보감》에 따르면 홍시는 숙취를 풀어주는 효능이 있으며, 이밖에 심장과 폐를 튼튼하게 하고 갈증을 없애주며 소화 기능을 좋아지게 하는 효능이 있다. 한편, 떫은맛을 제거하는 방법으로 소금물 또는 술에 담그는 방법도 있는데, 이를 침감 또는 침시라고 한다.The hongsi is also known as a year or yearbook. Hongshi is the name given in terms of the red color of persimmon, and the name of the new year is the texture is soft and soft. Persimmon is divided into persimmon and persimmon. Feeling is subdivided into complete feeling, incomplete feeling, incomplete persimmon. It is because it contains a tannin ingredient called diosphrin in the perspiration. Because this ingredient is water-soluble (water-soluble), it mixes with saliva in the mouth and melts to give a bitter taste. The elimination of this bitter taste is called de-picking. There is a natural way to get rid of the bitter taste, to keep it so that it becomes soft and flaky, and to remove the bitter taste artificially. Anthropogenic methods include hot tap dehydration, alcohol dephosphorization, gas dephosphorization, freeze-thaw dehydration, and the like, which are traditionally introduced in farmhouses. In this case, the depolarization only changes the water-soluble tannin component to insoluble (insoluble) and does not remove the tannin component. According to Donguibogam, Hongsi has the effect of releasing a hangover, and it has the effect of strengthening the heart and lungs, eliminating thirst, and improving the digestive function. On the other hand, there is a method of removing the bitter taste by immersing it in brine or alcohol, which is called impregnation or penetration.
상기 호도육은 호두살로서 신(腎)이 허(虛)해서 골질이 약화되어 생긴 요통(腰痛)을 치료하고 폐신(肺腎)이 허약해서 오는 해수(咳嗽), 천식 등을 치료하는 효능이 있는 약재이다.It is a treatment for the low back pain caused by weakness of the bone due to the wrinkle of the walnut flesh and the treatment for the cough and asthma that are caused by weakness of the lung kidney. Is a medicinal product.
상기 홍삼은 인삼의 재배 적지에서 생산된 좋은 품질의 6년근 수삼을 엄선하여 껍질을 벗기지 않은 상태로 장시간 증기로 쪄서 건조시킨 담황갈색 또는 담적갈색을 띠는 인삼이다. 인삼은 대개 4년까지는 똑같이 자라지만 4년 이후부터는 토양, 환경, 재배자의 기술에 따라 질이 크게 달라진다. 환경과 재배기술이 맞지 않으면 대부분 4년 이후부터 인삼이 썩기 시작한다. 또 6년이 넘으면 대부분의 인삼에서 목질화(나무처럼 딱딱해지는 것)가 진행된다. 홍삼의 제조 공정에서 우리 몸에 좋은 여러 가지 새로운 생리활성 성분들이 생성된다. 이들 성분들은 수삼이나 백삼에는 없는 홍삼 특유의 성분이다. 또한 홍삼은 수삼 등에 비해 오래 보관할 수 있다. 홍삼 성분 함유 제품의 기능성에는 원기 회복, 면역력 증진, 자양 강장에 도움 등이 있다. 홍삼에는 백삼에 없는 항산화 작용 성분인 말톨과 다양한 아미노산, 유기지방산 등이 함유되어 있다. 계절적으로 5월은 활동량이 늘어나면서 원기가 소진되기 쉬우므로 인삼을 복용할 적기(適期)이다. 특히 위장 등 소화기 계통이 약하면서 원기가 떨어진 사람에게 효과가 좋다.The red ginseng is ginseng which has been selected from 6-year-old root ginseng produced in suitable place of ginseng cultivation and is dried with steam for a long time in a state without peeling, and is dried in a dark yellowish brown or light reddish brown. Ginseng usually grows up to 4 years, but from 4 years onwards, quality varies greatly depending on the soil, environment, and technology of the grower. If the environment and cultivation techniques do not match, most of the ginseng begins to rot after 4 years. After more than 6 years, most ginsengs are ligneous (hardening like wood). In the manufacturing process of red ginseng, various new physiologically active ingredients which are good for our body are produced. These ingredients are unique to ginseng and white ginseng. Also, red ginseng can be kept longer than ginseng. Functional properties of red ginseng ingredients include refreshing, improving immunity, and helping nourishment. Red ginseng contains maltose which is an antioxidant ingredient not found in white ginseng and various amino acids and organic fatty acids. Seasonally, May is the best time to take ginseng as the amount of activity increases and it is prone to exhaustion. Especially in the digestive system such as gastrointestinal system is weak, the effect is good for people who have fallen.
상기 길경은 초롱꽃과의 도라지(Platycodon grandiflorum A. De Candolle)의 뿌리 또는 주피를 제거하여 만든 약재로, 길경이라는 이름은 뿌리가 단단하고 곧기 때문에 붙여진 것이다. 이 약은 냄새가 약간 있고 맛은 쓰고 매우며 성질은 어느 한쪽으로 치우치지 않고 평하다. 길경은 폐에 작용하여 해수와 가래가 많고 호흡이 불편한 증상을 치료하며, 폐를 맑게 하고 답답한 가슴을 풀어주며 뱃속의 찬 기운을 풀어주어 기침을 멈추고 담을 없앤다. 소변을 잘 보지 못하여 전신부종이 있고 소변양이 적을 때도 쓴다. 인후통, 감기로 인한 기침, 가래, 코막힘, 천식, 기관지염증, 흉막염, 두통, 오한, 편도선염 등에 사용한다. 약리작용으로 거담작용, 혈당강하작용, 콜레스테롤 강하작용, 개선균 억제작용이 보고되었다. 다른 이름으로 길경근(桔梗根), 경초(梗草), 고경(苦梗), 고길경(苦桔梗), 리여(利如), 방도(房圖), 백약(白藥), 부호(符扈) 등이 있다. Gakgyeong is a medicinal substance made by removing roots or juniper of Platycodon grandiflorum A. De Candolle, and the name Gakyung is attached because it is hard and straight. This medicine has a little smell, taste is very high, and the quality is flat without any bias. Gyungyung works on the lungs to treat symptoms with a lot of seawater and sputum, uncomfortable breathing, clearing the lungs, releasing the stiff chest, releasing cold air in the stomach, stopping the cough and removing the wall. I do not see my urine, I have generalized edema, and even when the amount of urine is small. Sore throat, cold cough, sputum, nasal congestion, asthma, bronchial inflammation, pleurisy, headache, chills and tonsillitis. The pharmacological action was reported to be a gadam action, a hypoglycemic action, a cholesterol lowering action, and an inhibiting action of improving bacteria. Other names include Giligyeong, Gyeongcho, Gamyeong, Gamgikyeong, Reiji, 房 圖, 白药, 扈 扈, .
상기 백합은 성질은 평하고 맛은 달며 독이 없다. 상한의 백합병(百合病)을 낫게 하고 대소변을 잘 나가게 하며 모든 사기와 헛것에 들려(百邪鬼魅) 울고 미친 소리로 떠드는 것을 낫게 한다. 고독(蠱毒)을 죽이며 유옹(乳癰), 등창(發背), 창종(瘡腫)을 낫게 한다. 여기에서 백합병(百合病)이라 함은 정신불안, 혼자 중얼거림, 구고, 소변적 등을 나타내는 병을 가리킨다.The lily is plain, flavorless and poisonous. It makes it better to cure the back-to-back merger (lily disease) and make it go well with all the scams and voids (100 邪 鬼 魅) It kills solitude (poison), and it heals the yuong (背 背 背), 背 背 (發 背) Here, the term "lupus disease" refers to a disease that manifests itself as mental anxiety, masturbation, guppy, urination.
상기 숙지황은 현삼과 식물인 지황(地黃) Rehmanneh glutinosa Libosch. var. purpurea Mak.의 뿌리를 쪄서 말린 것이다. 지황은 각지에서 심는다. 건지황(乾地黃)을 술에 불려 쪄서 말리는 조작을 3~4번 거듭한다. 또는 48시간 동안 쪄서 말린다. 맛은 달고 약간 쓰며 성질은 따뜻하다. 신경(腎經) · 간경(肝經) · 심경(心經) · 심포경(心包經)에 작용한다. 주로 혈액과 신음(腎陰)을 자양하고 정수(精髓)를 보충하며 머리털을 검게 한다. 약리 실험에서 항동맥경화 작용이 밝혀졌다. 혈허증(血虛證), 월경 불순(menoxenia), 신음허(腎陰虛)로 인한 골증(骨蒸), 잠잘 때 식은땀이 나는 데 쓴다. 소갈병(消渴病), 유정, 허리와 무릎이 연약한 데, 머리털이 일찍 희어지는 데도 쓴다. 하루 9~30g을 탕제 · 환제 · 산제 · 주제(酒劑) · 약엿[고제(膏劑)] 형태로 만들어 먹는다. 당뇨병에도 쓰는데 숙지황이 주약으로 되어 있는 육미환(六味丸)이 좋다. 식욕이 없고 소화가 안 되며 설사하는 환자에게는 쓰지 않는다. 이런 환자에게 꼭 써야 할 경우에는 귤피(橘皮) · 목향(木香)과 같은 소화약을 섞어서 쓴다. 숙지황을 쓸 때는 내복 · 무이(蕪荑)를 함께 쓰지 않는다.The above - mentioned Sukjwanghwang is the ginseng and the plant, which is geohang (黄黄) Rehmanneh glutinosa Libosch. there is. The root of purpurea mak. is steamed and dried. Rhubarb is planted in various places. It is called 지 황 黄 (黄 地 黄) to drink, and it is steamed and dried three or four times repeatedly. Or steamed for 48 hours. The taste is sweet, a little bit warm, and the nature is warm. It acts on the nerves (肾 经), liver (肝 经), heart (心 经), and cardiopathy (经 包 经). It nourishes mainly blood and groaning, replenishes pure water, and darkens hair. Atherosclerosis was found in pharmacological experiments. It is used for sweating when it sleeps, osteoporosis (血虛 证), menopenia (menoxenia), osteoporosis (肾阴 虛) due to osteoporosis. It is soft and has softness in waist and knee, and it also writes that hair gets whitish early. 9 to 30 grams a day is made in the form of a tablet, pills, powder, liquor, ginger (膏 剤). It is also good for meiwan (六味 丸), which is also used for diabetes, and has a lot of medicine. It is not appetite, it is not digestible, it is not used for diarrhea patients. If you need to use this medicine, you can mix it with digestive medication such as citrus peel and cinnamon. Do not use underwear, 荑 荑 when you use Suhjipgang.
상기 백복령은 흰솔풍령이라고도 한다. 전국 각지의 소나무를 베어 낸 곳에 자라며 재배도 한다. 베어 낸 지 여러 해 지난 소나무 뿌리에 기생하여 혹처럼 크게 자라는데, 소나무 그루터기 주변을 쇠꼬챙이로 찔러서 찾아낸다. 지름 30~50㎝ 쯤의 덩어리로 겉은 소나무 껍질처럼 거칠고 속은 희거나 분홍빛이 난다. 속이 흰 것은 백복령이라 하고 분홍빛인 것은 적복령이라고 하는데 백복령은 적송의 뿌리에 기생하고 적복령은 곰솔 뿌리에 기생한다. 그리고 솔뿌리를 둘러싼 것을 복신이라고 한다. 맛은 달고 심심하며 성질이 평(平)하여 보(補)하는 작용이 있고 이뇨작용을 하지만 강하지 않다. 옛날부터 강장제로 사용되었다. 폐경(肺經)·비경(脾經)·심경(心經)·신경(腎經)·방광경(膀胱經)에 작용하여 비장을 보하고 가래를 삭이며 정신을 안정시킨다. 약리실험 결과에 의하면 이뇨작용과 혈당량을 낮추는 작용, 진정작용 등을 하는 것으로 밝혀졌으며 면역 부활작용을 하는 것으로도 알려져 있다. 비장이 허(虛)하여 몸이 붓는 경우와 담음병에 사용한다. 그밖에 게우는 데나 복수·설사·건망증·수면장애 등에도 처방한다. 위·간·이자·신장 등의 질병에도 탁월한 효과가 있는 것으로 알려져 있으며, 질병을 앓고 난 후 허약한 사람이나 만성 위장병 환자 등의 치료를 위한 약재로 이용된다. 또 남녀의 임독성 질병은 물론 모든 성병과 부인병에도 효과가 있는 것으로 알려져 있다. The Baek Bok-ryeong is also called Bongsool Byeongryeong. It grows and grows where pine trees are scattered all over the country. It grows like a lump in a pine tree roots that has been bloomed for many years. The pine tree stubs around the stubble to find it. It is roughly 30 ~ 50㎝ in diameter and rough on the outside like a pine bark, white or pink inside. White is white rosette and pink rosette is red rooster. White roe is parasitized in the roots of red roots, and red rooster is parasitized in roots of roots. And the thing surrounding the solitary root is called the double. The taste is sweet and bored, the quality is flat, and there is a function to complement, and diuretic action, but not strong. It has long been used as a tonic. It acts on menopause (肺 经), necrosis (脾 经), heart (经 经), nerve (肾 经), bladder (膀胱 经) to see the spleen, sputum, and stabilizes the spirit. Pharmacological studies have shown that diuretic action, lowering of blood sugar level, sedation, etc. It is also known that the immune revival function. The spleen is hung (虛) to swell the body and used in the bottle. In addition, Ghee also prescribes such as diarrhea, diarrhea, forgetfulness, sleep disorder. It is known to have excellent effects on diseases such as stomach, liver, stomach, and kidney, and is used as a medicament for the treatment of people who are weak or chronic gastroenteritis after suffering from a disease. It is also known to be effective against sexually transmitted diseases as well as sexually transmitted diseases and women's diseases.
상기 유근피는 느릅나무과 느릅나무의 나무껍질 혹은 뿌리껍질이다. 비염, 축농증 완화, 피로회복, 소염작용, 호흡기 강화, 위염, 위궤양 등의 위장장애 예방 효과가 있다.The yukee pei are bark or root bark of elm and elm. Rhinitis, empyema relief, fatigue recovery, anti-inflammatory effect, respiratory strengthening, gastritis, stomach disorders such as gastric ulcers are effective to prevent.
상기 오미자는 과피와 과육은 달고 시며, 씨앗은 맵고 쓰며 전초는 짠맛을 가지고 있어 다섯가지의 맛을 모두 가지고 있기 때문에 붙여진 이름이라고 전해진다. 맛이 시다고만 언급하는 경우 오행 중에서 목(木)이 가장 우선하며 실제로 신맛이 주가되기 때문에 그러하다. 이 약은 약간 특이한 냄새가 있고 맛은 처음에는 시고 달며 성질은 따듯하다. 오미자는 해수, 천식에 유효하며 땀을 거두며 진액을 생성시켜 소갈증에 유효하다. 유정(遺精), 유뇨(遺尿), 소변 자주 보는 증상, 오래된 이질, 설사, 가슴이 뛰고 잠을 이루지 못하면서 꿈이 많은 증상에 쓰인다. 또한 기억력 감퇴, 집중력 감소 증상을 호전시키는 데 효과가 있다. 약리작용으로 대뇌피질 흥분작용, 혈압 강하작용, 거담, 진해 작용, 호흡 흥분 작용, 강심작용, 당 대사 촉진과 당분해작용, 세포 면역 기능 증강작용, 자궁 흥분 작용, 담즙 분비 촉진 작용, 위액 분비 조절 작용, 억균작용이 보고 되었다. The Omija is said to be a name given to it because it has all the five flavors of peel and flesh, the seeds are spicy and the outpouring has a salty taste. If you only mention that it is tasty, it is because the tree (tree) is the highest priority and the sour taste is actually the main one among the five. This medicine has a slight peculiar smell, and the taste is warm and sweet at first. Omija is effective for seawater and asthma, and it is effective for sweating and sweating by producing seaweed. Urine, uremia, urinary frequency, old diathesis, diarrhea, chest and sleep are not able to sleep, dreams are used for many symptoms. It is also effective in reducing symptoms of memory loss and concentration. Pharmacological action, cerebral cortex excitement, hypotensive action, genomic action, respiratory excitement, cardiac action, glucose metabolism promotion and glycosylation, cell immune function enhancement, uterus stimulation, bile secretion promoting action, gastric secretion regulation Action, and insect action have been reported.
상기 양파는 주로 요리에 양념재료로 이용한다. 껍질을 까서 비닐팩에 넣어 냉장고에 보관하여 먹으면 신속한 조리에 이용할 수 있다. 육류와 함께 섭취하면 영양의 균형을 이루며 양파의 퀘르세틴 성분이 항산화 작용을 하여 활성산소를 잡아준다. 양파는 열량이 적으며 콜레스테롤 농도를 저하시켜 다이어트에 좋다. 양파 특유의 매운맛과 자극적인 냄새는 유화알릴이라는 성분으로 소화액의 분비를 돕고 신진대사를 원활히 한다.The onion is mainly used as seasoning material for cooking. It can be used for quick cooking if it is eaten by storing it in a refrigerator after putting it in a plastic bag. When you consume it with meat, it balances nutrition, and the quercetin ingredient of onion makes antioxidant effect and catches active oxygen. Onion is low in calories and low in cholesterol concentration, so it is good for diet. The pungent flavor and irritating odor peculiar to onion are allyl allyl, which helps secretion of digestive juices and facilitates metabolism.
상기 산수유는 층층나무과의 낙엽교목인 산수유나무의 열매이다. 타원형의 핵과(核果)로서 처음에는 녹색이었다가 8~10월에 붉게 익는다. 종자는 긴 타원형이며, 능선이 있다. 약간의 단맛과 함께 떫고 강한 신맛이 난다. 10월 중순의 상강(霜降) 이후에 수확하는데, 육질과 씨앗을 분리하여 육질은 술과 차 및 한약의 재료로 사용한다. 과육(果肉)에는 코르닌(cornin)·모로니사이드(Morroniside)·로가닌(Loganin)· 타닌(tannin)·사포닌(Saponin) 등의 배당체와 포도주산·사과산·주석산 등의 유기산이 함유되어 있고, 그밖에 비타민 A와 다량의 당(糖)도 포함되어 있다. 종자에는 팔미틴산·올레인산·리놀산 등이 함유되어 있다. 성분 중 코르닌은 부교감신경의 흥분작용이 있는 것으로 알려져 있다. 예로부터 한방에서는 과육을 약용하였다. 《동의보감》 《향약집성방》 등에 의하면 강음(强陰), 신정(腎精)과 신기(腎氣)보강, 수렴 등의 효능이 있다고 한다. 두통·이명(耳鳴)·해수병, 해열·월경과다 등에 약재로 쓰이며 식은땀· 야뇨증 등의 민간요법에도 사용된다. 차나 술로도 장복하며, 지한(止汗)· 보음(補陰) 등의 효과가 있다. The above-mentioned corn oil is the fruit of the seedling tree which is a deciduous tree of the debris. Elliptical nuclei are green at first, but ripen reddish from October to October. Seeds are long oval and have ridges. It has a bitter sweetness and strong acidity. It is harvested after the frost fall in mid-October. The flesh is separated from the seeds and the meat is used as a material for sake, tea and Chinese medicine. The pulp contains the glycosides such as cornin, Morroniside, Loganin, tannin and saponin and organic acids such as wine, malic acid and tartaric acid. In addition, it contains vitamin A and a large amount of sugars. Seeds include palmitic acid, oleic acid, linoleic acid and the like. Among the components, cornin is known to have an excitatory action of parasympathetic nerves. From the past, the pulp was weakened in one batch. According to the "Dongbibogam" and the "Fragrant Bulgari", it is said that it has effects such as strengthening of 阴 阴, 肾 精 and 肾气, and convergence. It is used as a medicinal product for headache, tinnitus, sea water, fever and menstrual overuse. It is also used for folk remedies such as cold sweat and enuresis. There are effects such as stopping sweat, consonance and so on.
상기 감초는 특이한 냄새가 나며 맛은 달다. 감초는 모든 약의 독성을 조화시켜서 약효가 잘 나타나게 하며 장부의 한열과 사기를 다스리고 모든 혈맥의 소통을 잘 시키며 근육과 뼈를 튼튼히 한다. 약리작용은 해독작용, 간염, 두드러기, 피부염, 습진 등에 효과가 있다. 진해·거담, 근육이완, 이뇨작용, 항염작용이 있으며 소화성궤양을 억제한다.The licorice has a peculiar smell and taste is sweet. Licorice harmonizes the toxicity of all medicines and makes the medicinal effect appear, regulates the fever and morale of the book, makes good communication of all blood vessels, and strengthens the muscles and bones. Pharmacological action is effective in detoxification, hepatitis, urticaria, dermatitis, eczema. Jinhae, geomung, muscle relaxation, diuretic, anti-inflammatory action and suppress peptic ulcer.
본 발명에 있어서, "추출물"은 상기 백합, 황기, 산약, 홍삼, 생지황, 자완, 산수유, 백복령, 오매, 오미자, 길경, 유근피, 감초 및 육계를 혼합한 다음 통상의 방법에 의하여 추출한 추출물로서, 백합, 황기, 산약, 홍삼, 생지황, 자완, 산수유, 백복령, 오매, 오미자, 길경, 유근피, 감초 및 육계의 혼합물로부터 추출한 추출액뿐만 아니라 이의 건조 분말 또는 이를 이용하여 제형화된 모든 형태를 포함한다.In the present invention, the "extract" is an extract obtained by mixing the above lily, hwanggi, liquorice, red ginseng, raw persimmon, The present invention includes not only the extracts extracted from a mixture of lily, hwanggi, liquorice, red ginseng, raw persimmon, Jawwan, corn oil, Baekbokryeong, Ohmyum, Omija,
상기 추출물은 물 또는 유기 용매를 사용하여 추출할 수 있는데, 추출한 액은 액체 형태로 사용하거나 또는 농축 및/또는 건조하여 사용할 수 있다. 상기 유기 용매는 메탄올, 에탄올, 이소프로판올, 부탄올, 에틸렌, 아세톤, 헥산, 에테르, 클로로포름, 에틸아세테이트, 부틸아세테이트, 디클로로메탄, N,N-디메틸포름아미드(DMF), 디메틸설폭사이드(DMSO), 1,3-부틸렌글리콜, 프로필렌글리콜 또는 이들의 혼합용매이며, 추출물의 유효 성분이 파괴되지 않거나 최소화된 조건에서 실온 또는 가온하여 추출할 수 있다. The extract can be extracted with water or an organic solvent, and the extracted liquid can be used in liquid form or can be used by concentration and / or drying. The organic solvent may be selected from the group consisting of methanol, ethanol, isopropanol, butanol, ethylene, acetone, hexane, ether, chloroform, ethyl acetate, butyl acetate, dichloromethane, N, N-dimethylformamide (DMF), dimethylsulfoxide , 3-butylene glycol, propylene glycol, or a mixed solvent thereof. The extract can be extracted at room temperature or with heating under the condition that the active ingredient of the extract is not destroyed or minimized.
하나의 구체적 실시에서, 배, 홍시, 호도육, 홍삼, 길경, 백합, 숙지황, 백복령, 유근피, 오미자, 양파, 산수유 및 감초의 혼합 추출물은 10배 양(w/v)의 증류수를 넣어 90℃에서 4시간 추출한 후 여과지로 상층액을 회수하는 공정을 3회 반복하여 모은 후 감압건조시킴으로써 추출할 수 있다.In a specific embodiment, 10 times (w / v) distilled water was added to the mixed extract of Bae, Hongxi, Hodo, Red ginseng, Gyungyang, Lily, For 4 hours and then collecting the supernatant with filter paper is repeated 3 times, and then collected and dried under reduced pressure.
상기 추출 방법은 제한되지 않고, 예를 들어, 냉침추출, 초음파 추출, 환류 냉각 추출 등이 있다.The extraction method is not limited, and examples thereof include cold extraction, ultrasonic extraction, and reflux cooling extraction.
본 발명의 배, 홍시, 호도육, 홍삼, 길경, 백합, 숙지황, 백복령, 유근피, 오미자, 양파, 산수유 및 감초의 혼합 추출물은 추출, 분획, 또는 정제(분리, 분획)의 각 단계에서 얻어지는 모든 추출액, 분획, 정제물, 그들의 희석액, 농축액, 또는 건조물일 수 있다.The mixed extracts of the present invention can be obtained by extracting, fractionating, or purifying (extracting, fractionating) all the extracts obtained in each step of the present invention, such as pear, hongsi, hodo, red ginseng, gyeonggyeong, lily, An extract, a fraction, a purified product, a diluted solution thereof, a concentrate, or a dried product.
또한, 본 발명에서는 배, 홍시, 호도육, 홍삼, 길경, 백합, 숙지황, 백복령, 유근피, 오미자, 양파, 산수유 및 감초의 추출부위는 줄기, 뿌리, 잎, 꽃 등 모든 부위를 사용할 수 있으며, 특히 뿌리가 바람직하나, 어느 특정 부위로 한정되지 않는다.In the present invention, all parts such as stems, roots, leaves, flowers, etc. can be used as the extraction sites of pear, hongsi, hodo, red ginseng, gyeonggyeong, lily, The roots are particularly preferred, but are not limited to any particular site.
본 발명에 있어서, "추출 발효물"은 상기 추출물을 유산균 중에서 발효한 것을 의미한다. 이 때 발효균으로 유산균을 사용하며, 예를 들어, 락토바실러스 카제이(Lactobacillus casei), 락토바실러스 플란타룸(L. plantarum), 락토바실러스 애시도필러스(L. acidophilus), 락토바실러스 불가리쿠스(L.bulgaricus), 비피도박테리움 롱굼(Bifidobacterium longum), 비피도박테리움 비피둠(B. bifidum) 또는 이들의 혼합균을 사용할 수 있으며, 바람직하게는 락토바실러스 플란타룸(L. plantarum), 비피도박테리움 비피둠(B. bifidum) 또는 이들의 혼합균을 사용할 수 있으며, 특히 락토바실러스 플란타룸(L. plantarum) 및 비피도박테리움 비피둠(B. bifidum)이 바람직하다. In the present invention, "extracted fermented product" means that the extract is fermented in lactic acid bacteria. In this case, lactic acid bacteria are used as the fermenting bacteria, for example, Lactobacillus casei casei, L. plantarum , L. acidophilus , L. bulgaricus , Bifidobacterium longum , Bifidobacterium, Bifidobacterium longum , Bifidobacterium longum , B. bifidum or a mixed microorganism thereof may be used. Preferably, L. plantarum, B. bifidum or a mixed microorganism thereof can be used. And L. plantarum and B. bifidum are particularly preferable.
본 발명의 바람직한 구현예에서, 배, 홍시, 호도육, 홍삼, 길경, 백합, 숙지황, 백복령, 유근피, 오미자, 양파, 산수유 및 감초의 추출 발효물은 상기 추출물의 락토바실러스 플란타룸(L. plantarum) 발효물과 비피도박테리움 비피둠(B. bifidum) 발효물을 1:1 내지 1:3, 바람직하게는 1:2의 중량비로 혼합시켜 사용한다. In a preferred embodiment of the present invention, the extracted fermented products of Bae, Hongxi, Hodo, Red ginseng, Gyungyang, Lily, Seokjanghwang, Baekbokryeong, Yukuni, Omija, Onion, Sansui and Licorice are obtained from Lactobacillus planta (L. plantarum fermented with Bifidobacterium bifidum fermented at a weight ratio of 1: 1 to 1: 3, preferably 1: 2.
본 발명의 바람직한 구현예에서, 추출 발효물은 배, 홍시, 호도육, 홍삼, 길경, 백합, 숙지황, 백복령, 유근피, 오미자, 양파, 산수유 및 감초의 혼합 추출물에 유산균을 추출물 중량을 기준으로 4 내지 6 중량%의 양으로 접종하여 10 내지 20시간 동안 배양하여 제조될 수 있다.In a preferred embodiment of the present invention, the fermented extract is prepared by mixing lactic acid bacterium with the mixed extract of Bae, Hongxi, Hodo, Red ginseng, Gyungyang, Lily, Seokjanghwang, Baekbokryeong, Ryukyu, Omija, Onion, To 6% by weight and incubating for 10 to 20 hours.
본 발명의 바람직한 구현예에서, 상기 추출 발효물은 전체 조성물을 기준으로 하여 0.00001 내지 15.0 중량%, 보다 바람직하게는 0.0001 내지 10 중량%, 가장 바람직하게는 0.0001 내지 5 중량%의 양으로 포함될 수 있다. In a preferred embodiment of the present invention, the extracted fermented product may be contained in an amount of 0.00001 to 15.0 wt%, more preferably 0.0001 to 10 wt%, and most preferably 0.0001 to 5 wt%, based on the total composition .
본 발명의 식품 조성물은 유효성분으로서 배, 홍시, 호도육, 홍삼, 길경, 백합, 숙지황, 백복령, 유근피, 오미자, 양파, 산수유 및 감초의 추출 발효물뿐만 아니라, 식품 제조 시에 통상적으로 첨가되는 성분을 포함하며, 예를 들어, 단백질, 탄수화물, 지방, 영양소, 조미제 및 향미제를 포함한다. 상술한 탄수화물의 예는 모노사카라이드, 예를 들어, 포도당, 과당 등; 디사카라이드, 예를 들어 말토스, 슈크로스, 올리고당 등; 및 폴리사카라이드, 예를 들어 덱스트린, 사이클로덱스트린 등과 같은 통상적인 당 및 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 향미제로서 천연 향미제 [타우마틴, 스테비아 추출물 (예를 들어 레바우디오시드 A, 글리시르히진 등]) 및 합성 향미제(사카린, 아스파르탐 등)를 사용할 수 있다.The food composition of the present invention can be used not only as an active ingredient but also as an active ingredient in fermented foods such as pear, red pepper, hodo, red ginseng, royal ginseng, lily, And includes, for example, proteins, carbohydrates, fats, nutrients, flavoring agents, and flavoring agents. Examples of the above-mentioned carbohydrates are monosaccharides such as glucose, fructose, and the like; Disaccharides such as maltose, sucrose, oligosaccharides and the like; And polysaccharides such as dextrin, cyclodextrin and the like, and sugar alcohols such as xylitol, sorbitol and erythritol. Natural flavorings such as tau martin and stevia extract (e.g., rebaudioside A and glycyrrhizin) and synthetic flavorings (saccharine, aspartame, etc.) can be used as flavorings.
예컨대, 본 발명의 식품 조성물이 드링크제로 제조되는 경우에는 본 발명의 배, 홍시, 호도육, 홍삼, 길경, 백합, 숙지황, 백복령, 유근피, 오미자, 양파, 산수유 및 감초의 추출 발효물 이외에 구연산, 액상과당, 설탕, 포도당, 초산, 사과산, 과즙, 두충 추출액, 대추 추출액, 감초 추출액 등을 추가로 포함시킬 수 있다.For example, when the food composition of the present invention is prepared as a drink, in addition to the fermented extract of the present invention, such as pear, hongsi, hodo, red ginseng, gyeonggyeong, lily, Liquid fructose, sugar, glucose, acetic acid, malic acid, juice, mulberry extract, jujube extract, licorice extract, and the like.
한편, 본 발명의 구체적 실시예에서 배, 홍시, 호도육, 홍삼, 길경, 백합, 숙지황, 백복령, 유근피, 오미자, 양파, 산수유 및 감초의 추출 발효물에 대한 세포 독성 확인 결과 추출 발효물은 인체에 무해한 물질임이 밝혀졌다. 따라서, 본 발명의 추출 발효물은 독성 및 부작용이 거의 없으므로 장기간 사용 시에도 안심하고 사용할 수 있으므로 식품 조성물에 안전하게 적용할 수 있다.On the other hand, as a result of confirming the cytotoxicity of the fermented extract of Bae, Hongxi, Hodo, Red ginseng, Gyungyang, Lily, Seokjanghwang, Baekbokryeong, Yukuni, Omija, Onion, It was found to be a harmless substance. Therefore, the fermented extract of the present invention has little toxicity and side effects and can be safely used for long-term use, so that it can be safely applied to food compositions.
이와 같이, 본 발명의 배, 홍시, 호도육, 홍삼, 길경, 백합, 숙지황, 백복령, 유근피, 오미자, 양파, 산수유 및 감초의 추출 발효물을 유효성분으로 포함하는 조성물은 폐기 상승작용으로 호흡력을 증강시키고, 미세먼지. 이상기후 환경적요인 등으로 인한 폐음부족으로 마른기침 및 가래를 방지하고, 몸이 수척하고 기운이 없을 때에 복용하면 기력이 상승하고 폐를 보하여 만성적 폐질환을 예방 치료 할 수 있다. 또한, 폐를 보하고 기관지를 윤활하게 하는 보폐익기작용을 할 뿐만 아니라, 비염. 기관지 천식. 해수천식 등에도 높은 치료율이 나타낼 수 있다.As described above, the composition comprising the fermented extract of the present invention as an active ingredient in the fermented product of the present invention, such as pear, hongsi, hodo, red ginseng, gyeonggyeong, lily, And fine dust. Ideally, it is necessary to prevent dry cough and sputum due to shortage of environment due to lack of exhaustion due to environmental conditions. If you take it when you are sick and tired, your energy will increase and you will be able to prevent and treat chronic lung disease. In addition, the lungs to see the bronchial lubrication, as well as the action of the blind, rhinitis. Bronchial asthma. Seawater asthma can also be highly cured.
본 명세서에 첨부되는 다음의 도면들은 본 발명의 바람직한 실시예를 예시하는 것이며, 전술한 발명의 내용과 함께 본 발명의 기술사상을 더욱 이해시키는 역할을 하는 것이므로, 본 발명은 그러한 도면에 기재된 사항에만 한정되어 해석되어서는 아니 된다.
도 1은 배, 홍시, 호도육, 홍삼, 길경, 백합, 숙지황, 백복령, 유근피, 오미자, 양파, 산수유 및 감초의 혼합 추출물 제조과정을 나타내는 그래프이다.BRIEF DESCRIPTION OF THE DRAWINGS The accompanying drawings, which are incorporated in and constitute a part of the specification, illustrate exemplary embodiments of the invention and, together with the description of the invention, It should not be construed as limited.
Fig. 1 is a graph showing a process for producing a mixed extract of Bae, Hongxi, Hodo, Red ginseng, Gyungyang, Lily, Seokjanghwang, Baekbokryeong, Yukuni, Omija, Onion, Sansui and Licorice.
이하, 실시 예를 통하여 본 발명을 더욱 상세히 설명하고자 한다. 이들 실시 예는 오로지 본 발명을 보다 구체적으로 설명하기 위한 것으로, 본 발명의 요지에 따라 본 발명의 범위가 이들 실시 예에 의해 제한되지 않는다는 것은 당업계에서 통상의 지식을 가진 자에 있어서 자명할 것이다.Hereinafter, the present invention will be described in more detail with reference to Examples. It is to be understood by those skilled in the art that these embodiments are only for describing the present invention in more detail and that the scope of the present invention is not limited by these embodiments in accordance with the gist of the present invention .
<제조예 1> 배, 홍시, 호도육, 홍삼, 길경, 백합, 숙지황, 백복령, 유근피, 오미자, 양파, 산수유 및 감초의 추출물의 제조Preparation Example 1 Preparation of Extracts of Bae, Hongxi, Hodo Meat, Red Ginseng, Gyungyang, Lily, Seokjanghwang, Baekbokryeong, Yukuni, Omija, Onion, Sansui and Licorice
건조한배, 홍시, 호도육, 홍삼, 길경, 백합, 숙지황, 백복령, 유근피, 오미자, 양파, 산수유 및 감초를 하기 표 1에 나타낸 바와 같은 조성으로 혼합하여 10배 양(w/v)의 증류수를 넣어 90℃에서 4시간 추출한 후 여과지로 상층액을 회수하였다. 이러한 과정을 3회 반복하여 모은 후 감압건조시켜 -20℃에 보관하였다. 도 1은 배, 홍시, 호도육, 홍삼, 길경, 백합, 숙지황, 백복령, 유근피, 오미자, 양파, 산수유 및 감초의 혼합 추출물의 제조과정을 나타낸다. (W / v) of distilled water was added to the mixture as shown in Table 1, and the mixture was mixed with the mixture as shown in Table 1, After the extraction at 90 ° C for 4 hours, the supernatant was recovered with filter paper. This process was repeated three times and then dried under reduced pressure and stored at -20 ° C. Fig. 1 shows a process for producing a mixed extract of pear, hongsi, hodo, red ginseng, gyeonggyeong, lily, sorghum, baekbokgyeong, yukuni, omija, onion, corn oil and licorice.
<실시예 1> 추출 발효물의 제조Example 1 Preparation of Extracted Fermented Product
상기 제조예 1에서 수득된 배, 홍시, 호도육, 홍삼, 길경, 백합, 숙지황, 백복령, 유근피, 오미자, 양파, 산수유 및 감초의 추출물에 락토바실러스 플란타룸(L. plantarum) 균을 상기 추출물 중량을 기준으로 5 중량%의 양으로 접종하여 12시간 동안 배양하여 추출 발효물을 제조하였다. Lactobacillus plantarum (L. plantarum ) was added to the extracts obtained in Preparation Example 1 to obtain the extracts of pear, hongsi, hodo, red ginseng, gyeonggyeong, lily, sorghum, baekbokryeong, 5% by weight on the basis of weight, and cultured for 12 hours to prepare an extract fermented product.
또한, 상기 제조예 1에서 수득된 추출물에 비피도박테리움 비피둠(B. bifidum) 균을 추출물 중량을 기준으로 5 중량%의 양으로 접종하여 60 시간 동안 배양하여 추출 발효물을 제조하였다. Bifidobacterium bifidum was inoculated to the extract obtained in Preparation Example 1 in an amount of 5% by weight based on the weight of the extract and cultured for 60 hours to prepare an extract fermented product.
상기에서 제조된 배, 홍시, 호도육, 홍삼, 길경, 백합, 숙지황, 백복령, 유근피, 오미자, 양파, 산수유 및 감초의 추출물의 락토바실러스 플란타룸(L. plantarum) 발효물과 비피도박테리움 비피둠(B. bifidum) 발효물을 각각 1:2의 중량비로 혼합시켜 배, 홍시, 호도육, 홍삼, 길경, 백합, 숙지황, 백복령, 유근피, 오미자, 양파, 산수유 및 감초의 추출 발효물을 제조하였다. Lactobacillus planta (L. plantarum ) fermented product of the above-prepared extracts of pear, hongsi, hodo, red ginseng, gyeonggyeong, lily, Bifidum bifidum fermentation products were mixed at a weight ratio of 1: 2, respectively, and extracted fermented products of Bae, Hongsi, Hodo, Red ginseng, Gakyung, Lily, Seokgi, Baekbokryeong, Yukee, Omija, Onion, .
<시험예 1> 거담 활성 시험 ≪ Test Example 1 >
Engler 등의 방법(Engler H, Szelenyi I, J. Pharmacol. Moth., 1984, 11, 151~157, ; Jian-Hua Shang et al, J. Ethnopharmacology, 2010, 129, 293~298)을 이용하여 본 발명의 배, 홍시, 호도육, 홍삼, 길경, 백합, 숙지황, 백복령, 유근피, 오미자, 양파, 산수유 및 감초의 추출 발효물에 대한 거담 활성을 측정하였다.Using the method of Engler et al. (Engler H, Szelenyi I, J. Pharmacol. Moth., 1984, 11, 151-157; Jian-Hua Shang et al., J. Ethnopharmacology 2010,129, 293-298) The fermentation efficiency of the fermented extracts of the present invention was measured in the fermented product of the present invention, hongsi, hodo, red ginseng, gyeonggyeong, lily, sorghum, baekbokryeong, yukuni, omija, onion, corn oil and licorice.
이를 위해, 실험동물로는 체중 30~33g의 웅성 ICR 마우스(오리엔트바이오, 국내)를 각 군당 10마리씩 사용하였다. 전날 절식시킨 마우스에 실험군 별로 본 발명의 추출 발효물 및 비교약물인 암브록솔(250㎎/㎏, ambroxol, Sigma)과 염화암모늄(500㎎/㎏, ammonium chloride)을 경구투여하고, 30분 후 5% 페놀레드(phenol red)를 복강 주사하였다. 30분 후, 경추탈골하여 복부 대동맥을 방혈시킨 후 기관 (trachea) 전체를 절제하였다. 분리된 기관을 1㎖의 생리 식염수에 넣어 냉장 보관하였다. 24시간 후 냉장 보관된 기관을 3000rpm으로 10분간 원심분리하여 상등액에 1N 가성소다(NaOH)를 첨가(상등액 1㎖당 1N NaOH 0.1㎖)한 후에 546nm에서 흡광도를 측정하여 페놀레드의 농도로서 거담 활성을 측정하였으며 이에 대한 결과는 하기 표 2에 나타내었다.For this purpose, male ICR mice weighing 30 ~ 33g (Orient Bio, Korea) were used as experimental animals. The extracted fermented product of the present invention and amoxicillin (250 mg / kg, ambroxol, Sigma) and ammonium chloride (500 mg / kg, ammonium chloride) were orally administered to the mice fasted the previous day for 30 minutes 5% phenol red was intraperitoneally injected. After 30 minutes, the cervical dislocations were performed to bleed the abdominal aorta and the entire trachea was excised. The isolated organs were placed in 1 ml of physiological saline and refrigerated. After 24 hours, the refrigerated organs were centrifuged at 3000 rpm for 10 minutes, and 1 N sodium hydroxide (NaOH) was added to the supernatant (0.1 N NaOH per 1 ml of the supernatant). The absorbance at 546 nm was measured, The results are shown in Table 2 below.
상기 표 2에서 보는 바와 같이, 본 발명의 배, 홍시, 호도육, 홍삼, 길경, 백합, 숙지황, 백복령, 유근피, 오미자, 양파, 산수유 및 감초의 추출 발효물은 용량의존적으로 활성이 우수함을 알 수 있었으며, 특히 400㎎/㎏ 투여군에서 객담 배출능이 가장 우수한 활성을 나타냄을 확인할 수 있었다.As shown in Table 2, the fermented extracts of the present invention exhibited excellent activity in a dose-dependent manner, indicating that the fermented products of the present invention exhibited excellent activity in a dose-dependent manner. . In particular, it was confirmed that the sputum - releasing ability was the most excellent in the 400 mg / kg administration group.
<시험예 2> 진해 활성시험 ≪ Test Example 2 >
본 발명의 배, 홍시, 호도육, 홍삼, 길경, 백합, 숙지황, 백복령, 유근피, 오미자, 양파, 산수유 및 감초의 추출 발효물에 대한 진해 활성을 평가(American Journal of Respiratory and Critical Care Medicine, 1998, 158[1], 42-48)하기 위해 실시예 1의 추출 발효물을 기니피그에 투여한 후, 시트르산(citric acid)을 분무하여 기침을 유발한 다음 기침 횟수를 측정하였다. 시트르산은 기도의 감각 신경 활성을 연구하는데 많이 사용되는 물질로서, 흡입하게 되면 기관지수축, 코 자극, 기침, 기관지 과민반응 등이 발생하게 된다. Evaluation of Jinhae Activity on Extracted Fermented Extracts of Pears, Hongxi, Hodo Meat, Red Ginseng, Gyungyang, Lily, Sukjiwang, Baekbokryeong, Yukuni, Omiza, Onion, Sansui and Licorice (American Journal of Respiratory and Critical Care Medicine , 158 [1], 42-48), the extract fermented in Example 1 was administered to guinea pigs, citric acid was sprayed to induce coughing, and the number of coughs was measured. Citric acid is a substance that is widely used to study the sensory neuronal activity of airways. When inhaled, it causes bronchoconstriction, nasal irritation, coughing, and bronchial hyperresponsiveness.
실험동물로는 체중 350~400g의 웅성 Hartely계 기니피그(오리엔트바이오, 국내)를 각 군당 10~12마리씩 사용하였다. 전날 절식시킨 기니피그에 실험군 별로 실시예 2에서 제조된 천궁 및 후박의 혼합 생약의 분획물 및 비교약물인 테오브로민(50㎎/㎏, theobromine, 시그마)을 경구투여하고, 1시간 후에 동물에게 기침유발물질인 0.3M 시트르산을 10분간 분무하여 기침을 유발하였다. 기침유발물질에 노출되기 시작하는 시점으로부터 15분 동안 발생되는 기침 횟수를 Whole Body Plethysmometer (BUXCO)를 이용하여 측정하였고, 음성대조군(1% CMC 투여 군)의 기침 횟수를 기준으로 억제율(%)을 계산하여 하기 표 3에 나타내었다. 비교약물로 테오브로빈을 사용하였다.As experimental animals, male Hartely guinea pigs (Orient Bio, domestic) weighing 350 ~ 400g were used at 10 ~ 12 per group. The guinea pigs fasted the previous day were orally administered with the herbal composition fraction and the comparative drug theobromine (50 mg / kg, theobromine, Sigma) prepared in Example 2, and after 1 hour, 0.3 M citric acid was sprayed for 10 minutes to induce coughing. The number of coughs that occurred for 15 minutes from the start of exposure to the cough inducer was measured using a Whole Body Plethysmometer (BUXCO), and the percent inhibition (%) was calculated based on the number of coughs in the negative control (1% CMC group) The results are shown in Table 3 below. The comparative drug, tebuin, was used.
상기 표 3에서 보는 바와 같이, 본 발명의 배, 홍시, 호도육, 홍삼, 길경, 백합, 숙지황, 백복령, 유근피, 오미자, 양파, 산수유 및 감초의 추출 발효물은 용량의존적으로 활성이 우수함을 알 수 있었으며, 특히 400㎎/㎏ 투여군에서 기침 억제율이 가장 우수한 것을 확인할 수 있었다.As shown in Table 3, the fermented extracts of the present invention exhibited excellent activity in a dose-dependent manner, indicating that the fermented products of the present invention exhibited excellent activity in a dose-dependent manner. , And it was confirmed that the cough suppression rate was the most excellent in 400 mg / kg administration group.
하기에는 본 발명의 조성물을 위한 제제예를 예시한다.Examples of formulations for the composition of the present invention are illustrated below.
<제제예 1> 건강 식품의 제조≪ Formulation Example 1 > Preparation of health food
실시예 1의 배, 홍시, 호도육, 홍삼, 길경, 백합, 숙지황, 백복령, 유근피, 오미자, 양파, 산수유 및 감초의 추출 발효물 ........... 200 ㎎Extracted fermented product of the pear, hongsi, hodoki, red ginseng, gyeonggyeong, lily, sorghum, baekbokryeong, yukuni, omija, onion, corn oil and licorice of Example 1 ... 200 mg
비타민 혼합물 ...................................... 적량Vitamin mixture ......................................
비타민 A 아세테이트 ................................ 70 ㎍Vitamin A Acetate ............................ 70 ㎍
비타민 E .......................................... 1.0 ㎎Vitamin E .......................................... 1.0 mg
비타민 B1 .......................................... 0.13 ㎎Vitamin B1 .......................................... 0.13 mg
비타민 B2 .......................................... 0.15 ㎎Vitamin B2 .......................................... 0.15 mg
비타민 B6 .......................................... 0.5 ㎎Vitamin B6 .......................................... 0.5 mg
비타민 B12 ......................................... 0.2 ㎍Vitamin B12 .............................. 0.2 g
비타민 C ............................................. 10 ㎎Vitamin C ............................................. 10 mg
비오틴 ............................................... 10 ㎍Biotin ............................................... 10 μg
니코틴산아미드 ...................................... 1.7 ㎎Nicotinic acid amide .................................... 1.7 mg
엽산 ................................................. 50 ㎍Folic acid ................................................. 50 [mu] g
판토텐산 칼슘 ....................................... 0.5 ㎎Calcium pantothenate ....................................... 0.5 mg
무기질 혼합물 ........................................ 적량Mineral mixture ........................................
황산제1철 ........................................... 1.75 ㎎Ferrous sulfate ........................................... 1.75 mg
산화아연 ............................................ 0.82 ㎎Zinc oxide ............................................ 0.82 mg
탄산마그네슘 ........................................ 25.3 ㎎Magnesium carbonate ........................................ 25.3 mg
제1인산칼륨 .......................................... 15 ㎎Potassium Phosphate ......................................... 15 mg
제2인산칼슘 .......................................... 55 ㎎Secondary calcium phosphate ...................................... 55 mg
구연산칼륨 ........................................... 90 ㎎Potassium citrate ........................................... 90 mg
탄산칼슘 ............................................ 100 ㎎Calcium carbonate ............................................ 100 mg
염화마그네슘 ........................................ 24.8 ㎎Magnesium chloride ......................................... 24.8 mg
상기의 비타민 및 미네랄 혼합물의 조성비는 비교적 건강식품에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 그 배합비를 임의로 변형 실시하여도 무방하며, 통상의 건강식품 제조방법에 따라 상기의 성분을 혼합한 다음, 과립을 제조하고, 통상의 방법에 따라 건강식품 조성물 제조에 사용할 수 있다.Although the composition ratio of the above-mentioned vitamin and mineral mixture is comparatively mixed with a composition suitable for health food as a preferred embodiment, the compounding ratio may be arbitrarily modified, and the above ingredients are mixed according to a conventional method for producing healthy foods , Granules can be prepared and used in the manufacture of health food compositions according to conventional methods.
<제제예 2> 건강 음료의 제조≪ Formulation Example 2 > Preparation of health drink
실시예 1의 배, 홍시, 호도육, 홍삼, 길경, 백합, 숙지황, 백복령, 유근피, 오미자, 양파, 산수유 및 감초의 추출 발효물 ........... 200 ㎎Extracted fermented product of the pear, hongsi, hodoki, red ginseng, gyeonggyeong, lily, sorghum, baekbokryeong, yukuni, omija, onion, corn oil and licorice of Example 1 ... 200 mg
구연산 ............................................. 1000 ㎎Citric acid ............................................. 1000 mg
올리고당 ............................................ 100 gOligosaccharides ............................................ 100 g
매실농축액 ............................................ 2 gPlum concentrate ............................................ 2 g
타우린 ................................................ 1 gTaurine ................................................ 1 g
정제수를 가하여 ................................. 전체 900 ㎖Add purified water .................................. Total 900 ml
통상의 건강음료 제조방법에 따라 상기의 성분을 혼합한 다음, 약 1시간 동안 85℃에서 교반 가열한 후, 만들어진 용액을 여과하여 멸균된 2ℓ 용기에 취득하여 밀봉 멸균한 뒤 냉장 보관한 다음 본 발명의 건강음료 조성물 제조에 사용한다.The above components were mixed according to a conventional health drink manufacturing method, and the mixture was heated at 85 DEG C for about 1 hour with stirring, and the solution thus prepared was filtered to obtain a sterilized 2-liter container, which was sealed and sterilized, ≪ / RTI >
상기 조성비는 비교적 기호음료에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 수요계층, 수요국가, 사용용도 등 지역적, 민족적 기호도에 따라서 그 배합비를 임의로 변형 실시하여도 무방하다.Although the composition ratio is a mixture of the components suitable for the preferred beverage as a preferred embodiment, the compounding ratio may be arbitrarily varied depending on the regional and national preferences such as the demand level, the demanding country, and the intended use.
이와 같이, 본 발명의 배, 홍시, 호도육, 홍삼, 길경, 백합, 숙지황, 백복령, 유근피, 오미자, 양파, 산수유 및 감초의 추출 발효물을 유효성분으로 포함하는 조성물은 폐기 상승작용으로 호흡력을 증강시키고, 미세먼지. 이상기후 환경적요인 등으로 인한 폐음부족으로 마른기침 및 가래를 방지하고, 몸이 수척하고 기운이 없을 때에 복용하면 기력이 상승하고 폐를 보하여 만성적 폐질환을 예방 치료 할 수 있다. 또한, 폐를 보하고 기관지를 윤활하게 하는 보폐익기작용을 할 뿐만 아니라, 비염, 기관지 천식, 해수천식 등에도 높은 치료율이 나타낼 수 있다. 따라서, 본 발명의 배, 홍시, 호도육, 홍삼, 길경, 백합, 숙지황, 백복령, 유근피, 오미자, 양파, 산수유 및 감초의 추출 발효물은 폐기능 강화 및 폐질환 예방 및 개선을 위한 식품 조성물로서 안전하고 유용하게 사용될 수 있을 것으로 기대된다.As described above, the composition comprising the fermented extract of the present invention as an active ingredient in the fermented product of the present invention, such as pear, hongsi, hodo, red ginseng, gyeonggyeong, lily, And fine dust. Ideally, it is necessary to prevent dry cough and sputum due to shortage of environment due to lack of exhaustion due to environmental conditions. If you take it when you are sick and tired, your energy will increase and you will be able to prevent and treat chronic lung disease. In addition, not only does it perform the action of the abdominal afferent to see the lungs and lubricate the bronchial tubes, but also has a high treatment rate for rhinitis, bronchial asthma, and seaweed asthma. Therefore, the fermented extracts of the present invention can be used as a food composition for enhancing pulmonary function and preventing and improving pulmonary diseases as a fermented product of the present invention, such as pear, hongsi, hodo, red ginseng, gyeonggyeong, lily, It is expected to be safe and useful.
이상으로 본 발명의 특정한 부분을 상세히 기술하였는바, 당업계의 통상의 지식을 가진 자에게 있어서 이러한 구체적인 기술은 단지 바람직한 구현예일 뿐이며, 이에 본 발명의 범위가 제한되는 것이 아닌 점은 명백하다. 따라서, 본 발명의 실질적인 범위는 첨부된 청구항과 그의 등가물에 의하여 정의된다고 할 것이다.While the present invention has been particularly shown and described with reference to exemplary embodiments thereof, it is to be understood that the same is by way of illustration and example only and is not to be construed as limiting the scope of the present invention. Accordingly, the actual scope of the present invention will be defined by the appended claims and their equivalents.
Claims (6)
배 25 내지 35 중량%, 홍시 15 내지 25%, 호도육 5 내지 15 중량%, 홍삼 3 내지 5 중량%, 길경 3 내지 5 중량%, 백합 3 내지 5 중량%, 숙지황 3 내지 5 중량%, 백복령 3 내지 5 중량%, 유근피 3 내지 5 중량%, 오미자 3 내지 5 중량%, 양파 3 내지 5 중량%, 산수유 3 내지 5 중량% 및 감초 3 내지 5 중량%로 이루어진 혼합 추출물의 발효물을 유효성분으로 포함하는 폐기능 강화 또는 폐질환 예방 또는 개선을 위한 식품 조성물.The method according to claim 1,
The present invention relates to a method for producing a white pearl liquor, comprising the steps of blending 25 to 35% by weight of pearl, 15 to 25% of pearl, 5 to 15% by weight of pearl liquor, 3 to 5% by weight of red ginseng, 3 to 5% A fermented product of the mixed extract consisting of 3 to 5% by weight of the herbal composition, 3 to 5% by weight of rhizome, 3 to 5% by weight of omija, 3 to 5% by weight of onion, 3 to 5% Wherein the food composition is for enhancing pulmonary function or for preventing or improving pulmonary disease.
상기 추출물은 배, 홍시, 호도육, 홍삼, 길경, 백합, 숙지황, 백복령, 유근피, 오미자, 양파, 산수유 및 감초의 총량의 10배 양(w/v)의 증류수를 넣어 90℃에서 4시간 추출한 후 여과지로 상층액을 회수하는 공정을 3회 반복하여 모은 후 감압건조시켜 제조된 것임을 특징으로 하는 폐기능 강화 및 폐질환 예방 또는 개선을 위한 식품 조성물.The method according to claim 1,
The extracts were extracted with distilled water in an amount of 10 times (w / v) of the total amount of pear, red pepper, hodo, red ginseng, gilyung, lily, And recovering the supernatant with a filter paper, and collecting the supernatant by repeating the process three times, followed by drying under reduced pressure, thereby improving the lung function and preventing or improving lung disease.
상기 유산균이 락토바실러스 카제이(Lactobacillus casei), 락토바실러스 플란타룸(L. plantarum), 락토바실러스 애시도필러스(L. acidophilus), 락토바실러스 불가리쿠스(L.bulgaricus), 비피도박테리움 롱굼(Bifidobacterium longum), 비피도박테리움 비피둠(B. bifidum) 또는 이들의 혼합균인 것을 특징으로 하는 폐기능 강화 및 폐질환 예방 또는 개선을 위한 식품 조성물.The method according to claim 1,
When the lactic acid bacterium is Lactobacillus casei casei, L. plantarum , L. acidophilus , L. bulgaricus , Bifidobacterium longum , Bifidobacterium, Bifidobacterium longum , Bifidobacterium longum , B. bifidum , or a mixture thereof. The food composition for enhancing pulmonary function and for preventing or improving pulmonary disease.
상기 추출 발효물이 배, 홍시, 호도육, 홍삼, 길경, 백합, 숙지황, 백복령, 유근피, 오미자, 양파, 산수유 및 감초의 혼합 추출물에 락토바실러스 플란타룸(L. plantarum) 균을 상기 추출물 중량을 기준으로 4 내지 6 중량%의 양으로 접종하여 10 내지 20시간 동안 배양하여 발효된 것임을 특징으로 하는 폐기능 강화 및 폐질환 예방 또는 개선을 위한 식품 조성물.The method according to claim 1,
Lactobacillus plantarum (L. plantarum ) was added to the mixed extract of the extracted fermented product of Bae, Hongsei, Hodo, Red ginseng, Gyungyang, Lily, Seokjanghwang, Baekbokryeong, Yukuni, Omija, Onion, By weight, based on the total weight of the composition, and fermented for 10 to 20 hours.
상기 배, 홍시, 호도육, 홍삼, 길경, 백합, 숙지황, 백복령, 유근피, 오미자, 양파, 산수유 및 감초의 혼합 추출물을 유산균으로 발효시킨 추출 발효물이 전체 조성물을 기준으로 하여 0.00001 내지 15.0 중량%의 양으로 포함된 것을 특징으로 하는 폐기능 강화 및 폐질환 예방 또는 개선을 위한 식품 조성물.6. The method according to any one of claims 1 to 5,
The extracted fermented product obtained by fermenting the mixed extracts of Bae, Hongxi, Hodo, Red ginseng, Gakyung, Lily, Seokjanghwang, Baekbokryeong, Yukuni, Omija, Onion, Sansui and Licorice with lactic acid bacterium is 0.00001-15.0% Of the total weight of the food composition.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020160128172A KR20180037693A (en) | 2016-10-05 | 2016-10-05 | A food composition for preventing and improving lung diseases |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020160128172A KR20180037693A (en) | 2016-10-05 | 2016-10-05 | A food composition for preventing and improving lung diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20180037693A true KR20180037693A (en) | 2018-04-13 |
Family
ID=61974148
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020160128172A KR20180037693A (en) | 2016-10-05 | 2016-10-05 | A food composition for preventing and improving lung diseases |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20180037693A (en) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109125626A (en) * | 2018-09-28 | 2019-01-04 | 福建农林大学 | A kind of Yin nourishing and lung moistening Chinese medicine compound prescription smoke grenade liquid and preparation method thereof |
KR101969906B1 (en) * | 2018-10-18 | 2019-04-17 | 주식회사한국야쿠르트 | Composition for maintaing immunological homeostasis by settling immunological imbalance due to fine dust containing Lactobacillus casei HY2782 as effective component |
KR102034238B1 (en) * | 2019-05-16 | 2019-10-18 | 주식회사 네이처셀 | Manufacturing Method of Complex Fermentation Liquid For Bronchial Health Using Natural Material |
WO2020040462A1 (en) * | 2018-08-24 | 2020-02-27 | 주식회사 성균바이오텍 | Composition comprising plant extract as effective ingredient for preventing or treating particulate matter-induced respiratory disease |
KR102165929B1 (en) * | 2020-08-24 | 2020-10-14 | (주)녹십자웰빙 | Composition for prevention or treatment of respiratory diseases or inflammation induced by particulate matter comprising novel lactic acid bacteria |
KR102169920B1 (en) | 2019-12-20 | 2020-10-26 | 문경시 | A composition comprising extract of Schisandra chinensis, pear and Platycodon grandiflorum for preventing or treating respiratory inflammatory diseases |
KR20210109868A (en) * | 2020-02-28 | 2021-09-07 | 김왕권 | Food composition for prevention of respiratory diseases from particulate matter |
WO2021235713A1 (en) * | 2020-05-22 | 2021-11-25 | (주)녹십자웰빙 | Composition for treating respiratory diseases or inflammatory diseases caused by fine dust stimulation, containing lactic acid bacteria |
KR20220057345A (en) | 2020-10-29 | 2022-05-09 | 박성심 | Methods of manufacture of lung health supplement herbal medicine using sea trumpet as the main ingredient |
KR20220094678A (en) | 2020-12-29 | 2022-07-06 | 재단법인 진안홍삼연구소 | A composition comprising ginseng for preventing, improving or treating chronic obstructive pulmonary disease by fine dust |
KR20220094660A (en) | 2020-12-29 | 2022-07-06 | 재단법인 진안홍삼연구소 | A composition comprising ginseng for preventing, improving or treating chronic obstructive pulmonary disease by cigarette |
KR20220094614A (en) | 2020-12-29 | 2022-07-06 | 재단법인 진안홍삼연구소 | A composition comprising ginseng for preventing, improving or treating chronic obstructive pulmonary disease |
-
2016
- 2016-10-05 KR KR1020160128172A patent/KR20180037693A/en not_active Application Discontinuation
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020040462A1 (en) * | 2018-08-24 | 2020-02-27 | 주식회사 성균바이오텍 | Composition comprising plant extract as effective ingredient for preventing or treating particulate matter-induced respiratory disease |
CN109125626A (en) * | 2018-09-28 | 2019-01-04 | 福建农林大学 | A kind of Yin nourishing and lung moistening Chinese medicine compound prescription smoke grenade liquid and preparation method thereof |
KR101969906B1 (en) * | 2018-10-18 | 2019-04-17 | 주식회사한국야쿠르트 | Composition for maintaing immunological homeostasis by settling immunological imbalance due to fine dust containing Lactobacillus casei HY2782 as effective component |
KR102034238B1 (en) * | 2019-05-16 | 2019-10-18 | 주식회사 네이처셀 | Manufacturing Method of Complex Fermentation Liquid For Bronchial Health Using Natural Material |
KR102169920B1 (en) | 2019-12-20 | 2020-10-26 | 문경시 | A composition comprising extract of Schisandra chinensis, pear and Platycodon grandiflorum for preventing or treating respiratory inflammatory diseases |
KR20210109868A (en) * | 2020-02-28 | 2021-09-07 | 김왕권 | Food composition for prevention of respiratory diseases from particulate matter |
WO2021235713A1 (en) * | 2020-05-22 | 2021-11-25 | (주)녹십자웰빙 | Composition for treating respiratory diseases or inflammatory diseases caused by fine dust stimulation, containing lactic acid bacteria |
KR102165929B1 (en) * | 2020-08-24 | 2020-10-14 | (주)녹십자웰빙 | Composition for prevention or treatment of respiratory diseases or inflammation induced by particulate matter comprising novel lactic acid bacteria |
KR20220057345A (en) | 2020-10-29 | 2022-05-09 | 박성심 | Methods of manufacture of lung health supplement herbal medicine using sea trumpet as the main ingredient |
KR20220094678A (en) | 2020-12-29 | 2022-07-06 | 재단법인 진안홍삼연구소 | A composition comprising ginseng for preventing, improving or treating chronic obstructive pulmonary disease by fine dust |
KR20220094660A (en) | 2020-12-29 | 2022-07-06 | 재단법인 진안홍삼연구소 | A composition comprising ginseng for preventing, improving or treating chronic obstructive pulmonary disease by cigarette |
KR20220094614A (en) | 2020-12-29 | 2022-07-06 | 재단법인 진안홍삼연구소 | A composition comprising ginseng for preventing, improving or treating chronic obstructive pulmonary disease |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR20180037693A (en) | A food composition for preventing and improving lung diseases | |
KR101090284B1 (en) | Tonic comprising red ginseng and deer antlers extracts and manufacturing method thereof | |
KR101738594B1 (en) | Prepatation method of black platycodon syrup and black platycodon syrup | |
KR100372561B1 (en) | Compositions effective for removing hangover which contains natural herb tea extracts and health supplementing foods containing the same as an effective ingredient | |
KR101880894B1 (en) | Food composition comprising the mixed herbal extract as an active ingredient | |
KR100968109B1 (en) | Calcium?compound containing natural product composition for curing a hangover and preparation method thereof | |
CN104351587A (en) | Cattle feed and preparation method thereof | |
KR102136052B1 (en) | Composition for Liver Protection Containing Hub Extract and Beverage Thereof | |
KR101930277B1 (en) | Composition for Preventing and Improving Hangover | |
KR100552398B1 (en) | An alcohol detoxification beverage comprising extract of horse bean | |
CN108813501B (en) | Health-preserving honey paste with functions of clearing heat, moistening lung, relieving cough, reducing phlegm, relieving asthma and regulating human body functions | |
KR20090127970A (en) | Uncooked food pill and its manufacturing process | |
KR101195109B1 (en) | composition of health food | |
KR101961356B1 (en) | Composition of Extract of Cirsium Japonicum and Manufacturing method thereof | |
KR20170010474A (en) | Manufacturing method of beverage for relieving hangovers and the beverage | |
CN106942415A (en) | It is a kind of suitable for rattan mother-in-law's tea solid beverage of alleviating hangover and inducing resuscitation and preparation method thereof | |
CN110151851A (en) | Compound and its application based on a kind of Radix Glycyrrhizae medicine pair by honeysuckle | |
KR101731899B1 (en) | health supplement food to Improve Respiratory Diseases and method for manufacturing the same | |
KR20190032139A (en) | A food composition for preventing and improving lung diseases | |
KR102136053B1 (en) | Composition for Removing Hangover Comprising Herb Extract and Beverage Thereof | |
KR20220052606A (en) | Bamboo salt Laver-bugak comprising Ginkgo and Bellflower and Manufacturing method of the same | |
KR101068128B1 (en) | Natural product composition containing ionized calcium fertilized unmilled rice for activating alcohol excretion,aldehyde metabolism and curing a hangover and preparation method thereof | |
JP2005154411A (en) | Composition for preventing/removing hangover | |
CN109662317A (en) | A kind of composition and its application method for stomach conditioning health | |
CN109170052A (en) | A kind of dendrobium nobile stomach-nourishing health tea and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E601 | Decision to refuse application |